3 To the best of our knowledge, no studies have evaluated DBP and free and bioavailable 25(OH)D levels in melanoma patients.
Circulating vitamin Debinding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: A case-control study To the Editor: Novel risk factors and biomarkers are being sought for cutaneous melanoma, given its increasing incidence and mortality worldwide. Although ultraviolet radiation is an established melanoma risk factor, paradoxically, vitamin D (VD) deficiency has been linked to increased melanoma risk and progression with conflicting results. 1 A majority of 25-hydroxyvitamin D [25(OH)D] and 1,25(OH) 2 D circulate bound to VD-binding protein (DBP) (85%-90%) and albumin (10%-15%), with \1% circulating in its free form. Low DBP levels have been described as a potential cancer risk biomarker, adding complexity to the VD axisecancer association. 2 Recent studies have shown a better correlation of bioavailable ( free plus albumin-bound) 25(OH)D than total 25(OH)D with measures of bone mineral metabolism. 3 Higher free 25(OH)D levels have also been associated with decreased risk for colorectal but not breast cancer. 3 To the best of our knowledge, no studies have evaluated DBP and free and bioavailable 25(OH)D levels in melanoma patients.
A case-control study was conducted prospectively. The scientific ethics committee of our institution approved this study. We included adult patients with a recent diagnosis of melanoma; blood samples were taken \3 weeks after diagnosis. Exclusion criteria were VD-supplement use during the previous 6 months, pregnancy, lactation, immunosuppression, bone metabolism alterations, granulomatous diseases, and concurrent cancer. The control group included healthy age-, sex-, season-and skintypeepaired patients without histories of dysplastic nevi or skin cancer and without other exclusion criteria reported for melanoma patients.
We measured serum 25(OH)D (by liquid chromatographyetandem mass spectrometry) and DBP (by polyclonal ELISA, AssayPro LLC, St. Charles, MO). 25(OH)D levels were categorized as deficient (\50 nmol/L), insufficient (50-74 nmol/L), or sufficient ($75 nmol/L) according to current Endocrine Society guidelines. 4 Free and bioavailable 25(OH)D were calculated as described. 5 We included 40 melanoma patients and 56 controls; clinical and laboratory characteristics are shown in Table I . DBP levels were significantly lower in melanoma patients than in controls (P \ .001). Upon comparing invasive melanoma, melanoma in situ, and controls, a significant trend of higher DBP levels corresponding with healthier populations was observed (P ¼ .002, Fig 1) . No association was found between DBP levels and pTNM groups (P ¼ .91) or Breslow index (P ¼ .32). Total, bioavailable, and free 25(OH)D levels were similar between melanoma and control groups and between melanoma in situ and invasive melanoma groups. In addition, there were no associations between total, bioavailable, or free 25(OH)D and Breslow index or pTNM (all P [.05).
Herein, we show that low circulating DBP levels are associated with diagnosis of melanoma, possibly constituting a novel risk factor for its development. Upon analyzing invasive and melanomas in situ as separate subgroups, this association was strengthened, showing the lowest DBP levels in invasive melanomas. In addition to plasma VD carriage, multiple additional functions of DBP have been recently described. 6 DBP can naturally be converted to macrophage activation factor (DBP-MAF) by glycosylation. This has led some to hypothesize that cancer patients might have decreased DBP-MAF glycosylation, impeding macrophage activation against cancer cells, among other potential anticancer mechanisms. 6 Despite the association of DBP with melanoma, no association was found between total, bioavailable, or free 25(OH)D concentrations with melanoma at diagnosis. Measurement of DBP and free 25(OH)D should be incorporated into future studies to better define the role of the VD pathway in melanoma.
Cristi an Navarrete-Dechent, MD, A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash
To the Editor: An acneiform rash develops on the face and trunk in up to 90% of patients receiving cetuximab. The impact this rash has on the quality of life (QoL) and psychosocial well-being can be severe, and its development might lead to reduced cetuximab dosing and adverse clinical outcomes. 1 Current interventions include topical steroids or oral antibiotics (sometimes as part of a multi-drug regimen), which might be associated with adverse events (AEs), microbial resistance, and polypharmacy. To date, no topical agent in a prospective, randomized study has shown the benefit of preventing epidermal growth factor receptor inhibitor (EGFRI)einduced acneiform rash.
Dapsone exerts its anti-inflammatory effects via suppression of neutrophil recruitment; inhibition of the release of prostaglandins, leukotrienes, and lipopolysaccharide-stimulated interleukin 8 production in human keratinocytes 2, 3 ; and a decrease of mononuclear cell tumor necrosis factor-production. 4, 5 It also blocks the generation of toxic, oxygen-derived radicals, thereby protecting 
Fig 1.
Lesion count differences between control-treated and dapsone-treated sides. Presented are the individual participant trajectories for lesion count differences between control-treated and dapsone-treated sides of the face and chest for those participants who completed the day 28 6 2 evaluation. Values [0 indicate higher lesion counts on the control-treated side than on the dapsonetreated side of the body. Also included is a fitted trajectory to depict the overall trend in the difference in lesion counts for the group as a whole.
